(Q38107513)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Advances in prostate cancer chemoprevention: a translational perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Dhanya Nambiar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

1 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

65 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

12-25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Precursors of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

The complex genetic epidemiology of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Mechanisms of action of novel agents for prostate cancer chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

The Role of Soy Products in Reducing Risk of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Soy product and isoflavone consumption in relation to prostate cancer in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Safety of purified isoflavones in men with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Orally administered isoflavones are present as glucuronides in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Protective effect of green tea against prostate cancer: A case‐control study in southeast China

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Green tea consumption and prostate cancer risk in Japanese men: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Traditional Japanese diet and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Mass screening-based case-control study of diet and prostate cancer in Changchun, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth facto

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

A single ascending dose study of epigallocatechin gallate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

21 January 2018

The targets of curcumin.

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Dose escalation of a curcuminoid formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Bioavailability of curcumin: problems and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Advanced drug delivery systems of curcumin for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Selenium and human health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

A prospective study of tomato products, lycopene, and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F01635581.2013.785006

10.1080/01635581.2013.785006

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682779%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference